

1 **Title**

2 Blood RNA signatures outperform CRP triage of tuberculosis lymphadenitis and pericarditis.

3 **Authors**

4 Tiffeney Mann (MSc)^{1*}, Stephanie Minnies (PhD)^{2*}, Rishi K Gupta (PhD)^{3*}, Byron WP Reeve (PhD)^{2§}, Georgina
5 Nyawo (PhD)², Zaida Palmer (MSc)², Charissa Naidoo (PhD)², Anton Doubell (MMed, PhD)⁴, Alfonso Pecararo
6 (MMed, PhD)⁴ Thadathilankal-Jess John (MBCChB)⁴, Pawel Schubert (MPhil)^{5,6}, Claire J Calderwood (MRCP)⁷,
7 Aneesh Chandran (PhD)¹, Grant Theron (PhD)^{2‡}, Mahdad Noursadeghi (PhD)^{1‡}

8 *Co-first authors, ‡Co-senior authors, §Died on 28th September 2023

9 **Affiliations**

- 10 1. Division of Infection and Immunity, University College London, London, UK
11 2. DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research
12 Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of
13 Medicine and Health Sciences, Stellenbosch University, Cape Town
14 3. UCL Respiratory, Division of Medicine, University College London, London, UK
15 4. Department of Medicine, Division of Cardiology, Stellenbosch University & Tygerberg Academic Hospital,
16 South Africa
17 5. National Health Laboratory Service, Tygerberg Hospital, Cape Town, Western Cape, South Africa.
18 6. Division Anatomical Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape
19 Town, Western Cape, South Africa.
20 7. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene
21 & Tropical Medicine, London, UK

22 **Correspondence**

23 Professor Mahdad Noursadeghi (<https://orcid.org/0000-0002-4774-0853>), Division of Infection & Immunity,
24 Cruciform Building, University College London, London WC1E 6BT, United Kingdom. Email:
25 m.noursadeghi@ucl.ac.uk

26 Professor Grant Theron, (<https://orcid.org/0000-0002-9216-2415>), DSI-NRF Centre of Excellence for
27 Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis
28 Research; and Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences,
29 Stellenbosch University, Cape Town, South Africa. Email: gtheron@sun.ac.za

30 **Research in context**

31 ***Evidence before this study***

32 Blood RNA biomarker signatures and CRP measurements have emerged as potential triage tests for TB, but
33 evidence is mostly limited to their performance in pulmonary TB. Microbiological diagnosis of extrapulmonary
34 TB (EPTB) is made challenging by the need for invasive sampling to obtain tissue from the site of disease.
35 This is compounded by lower sensitivity of confirmatory molecular tests for EPTB compared to their
36 performance in pulmonary disease. We performed a systematic review of diagnostic accuracy studies of blood
37 RNA biomarkers or CRP measurements for EPTB, which could mitigate the need for site-of-disease sampling
38 for the diagnosis of TB. We searched PubMed up to 1st August 2023, using the following criteria:
39 “extrapulmonary [title/abstract] AND tuberculosis [title/abstract] AND biomarker [title/abstract]”. Although
40 extrapulmonary TB was included in several studies, none focused specifically on EPTB or included an
41 adequate number of EPTB cases to provide precise estimates of test accuracy.

42 ***Added value of this study***

43 To the best of our knowledge, we report the first diagnostic accuracy study of blood RNA biomarkers and CRP
44 for TB among people with EPTB syndromes. We examined the performance of seven previously identified
45 blood RNA biomarkers as triage tests for TB lymphadenitis and TB pericarditis compared to a microbiology
46 reference standard among people referred to hospital for invasive sampling in a high TB and HIV prevalence
47 setting. Multiple blood RNA biomarkers showed comparable diagnostic accuracy to that previously reported
48 for pulmonary TB in both EPTB disease cohorts, irrespective of HIV status. All seven blood RNA biomarkers
49 showed superior diagnostic accuracy to CRP for both lymphadenitis and pericarditis, but failed to meet the
50 combined >90% sensitivity and >70% specificity recommended for a blood-based diagnostic triage test by
51 WHO. Nonetheless, in decision curve analysis, an approach of using the best performing blood RNA biomarker
52 to trigger confirmatory microbiological testing showed superior clinical utility in clinical services seeking to
53 reduce the number needed to test (using invasive confirmatory testing) to less than 4 for each EPTB case
54 detected. If acceptable to undertake invasive testing in more than 4 people for each true case detected, then
55 a test-all approach will provide greater net benefit in this TB/HIV hyperendemic setting.

56 ***Implications of all the available evidence***

57 Blood RNA biomarkers show some potential as diagnostic triage tests for TB lymphadenitis and TB pericarditis,
58 but do not provide the level of accuracy for blood-based triage tests recommended by WHO for community-
59 based tests. CRP has inferior diagnostic accuracy to blood RNA biomarkers and cannot be recommended for
60 diagnostic triage among people with EPTB syndromes referred for invasive sampling.

61 **Abstract**

62 **Background**

63 Limited data are available on the diagnostic accuracy of blood RNA biomarker signatures for extrapulmonary
64 TB (EPTB). We addressed this question among people investigated for TB lymphadenitis and TB pericarditis,
65 in Cape Town, South Africa.

66 **Methods**

67 We enrolled 440 consecutive adults referred to a hospital for invasive sampling for presumptive TB
68 lymphadenitis (n=300) or presumptive TB pericarditis (n=140). Samples from the site of disease underwent
69 culture and/or molecular testing for *Mycobacterium tuberculosis* complex (Mtb). Discrimination of patients with
70 and without TB defined by microbiology or cytology reference standards was evaluated using seven previously
71 reported blood RNA signatures by area under the receiver-operating characteristic curve (AUROC) and
72 sensitivity/specificity at predefined thresholds, benchmarked against blood C-reactive protein (CRP) and the
73 World Health Organization (WHO) target product profile (TPP) for a TB triage test. Decision curve analysis
74 (DCA) was used to evaluate the clinical utility of the best performing blood RNA signature and CRP.

75 **Results**

76 Data from 374 patients for whom results were available from at least one microbiological test from the site of
77 disease, and blood CRP and RNA measurements, were included. Using microbiological results as the
78 reference standard in the primary analysis (N=204 with TB), performance was similar across lymphadenitis
79 and pericarditis patients. In the pooled analysis of both cohorts, all RNA signatures had comparable
80 discrimination with AUROC point estimates ranging 0.77-0.82, superior to that of CRP (0.61, 95% confidence
81 interval 0.56-0.67). The best performing signature (Roe3) achieved an AUROC of 0.82 (0.77-0.86). At a
82 predefined threshold of 2 standard deviations (Z2) above the mean of a healthy reference control group, this
83 signature achieved 78% (72-83%) sensitivity and 69% (62-75%) specificity. In this setting, DCA revealed that
84 Roe3 offered greater net benefit than other approaches for services aiming to reduce the number needed to
85 investigate with confirmatory testing to <4 to identify each case of TB.

86 **Interpretation**

87 RNA biomarkers show better accuracy and clinical utility than CRP to trigger confirmatory TB testing in patients
88 with TB lymphadenitis and TB pericarditis, but still fall short of the WHO TPP for TB triage tests.

89 **Funding**

90 South African MRC, EDCTP2, NIH/NIAID, Wellcome Trust, NIHR, Royal College of Physicians London.

91 Introduction

92 Delays in the diagnosis of tuberculosis (TB) remain a significant barrier to reducing the associated morbidity
93 and mortality for individuals, and effectiveness of world-wide TB control programmes at population level¹. It is
94 estimated that extrapulmonary disease comprises approximately 10-30% of new or relapse TB cases^{1,2}. Whilst
95 TB incidence has slowly declined over the past 20 years, EPTB incidence has not³⁻⁵. Microbiological diagnosis
96 of TB has mostly relied on sampling the site of disease. In pulmonary TB, non-invasive sputum expectoration
97 can provide appropriate samples for microbiological diagnosis. Diagnosis of extrapulmonary TB (EPTB)
98 remains more challenging because of the need for invasive procedures to sample the site of disease,
99 necessitating access to hospitals with specialised infrastructure and expertise that are resource intensive. In
100 addition, confirmatory molecular tests for TB have lower sensitivity in EPTB compared to pulmonary disease^{6,7}.
101 These barriers have the greatest impact in low and middle income countries (LMIC) where EPTB incidence
102 may be systematically underestimated, particularly among people living with HIV (PLWH) who have higher risk
103 of EPTB^{8,9}. To address this limitation in both EPTB and sputum scarce pulmonary TB, and to mitigate against
104 the health economic barriers to systematic microbiological testing, the World Health Organization (WHO) have
105 recommended development of sensitive, cheap, point of care blood-based triage tests to enable more precise
106 targeting of patients for confirmatory diagnostic testing¹⁰.

107 Blood RNA biomarkers and C-reactive protein (CRP) measurements have emerged as leading candidates for
108 blood-based triage tests for TB^{11,12}. CRP is a hepatocyte-derived acute phase protein. Increased levels in the
109 circulation are induced by interleukin (IL)-6 and other acute phase cytokine activity. It is most widely used as
110 non-specific biomarker of bacterial infections¹³. The advent of a cheap quantitative point of care test for CRP
111 has made it a particularly attractive as a triage test for TB in LMIC settings, where it has been evaluated for
112 screening for pulmonary TB in PLWH before starting antiretroviral therapy¹⁴ and among people presenting with
113 TB symptoms¹⁵. The diagnostic accuracy of CRP for EPTB has not been tested.

114 Numerous candidate blood RNA biomarkers of TB have been reported. They range from single gene
115 transcripts to multi-gene signatures. We have shown that the best performing blood RNA biomarkers of TB
116 are co-correlated and reflect canonical host immune responses downstream of tumour necrosis factor (TNF)
117 and interferon (IFN) signalling¹⁶. Although previous diagnostic accuracy studies of TB blood RNA biomarkers
118 have included people with EPTB, they were not powered to evaluate differences in biomarker accuracy
119 between pulmonary and extrapulmonary disease. No studies to date have evaluated diagnostic accuracy
120 exclusively among people with signs and symptoms suggestive of EPTB.

121 EPTB can affect any organ system. On this spectrum, TB lymphadenitis is among the commonest extra-
122 thoracic sites of disease²⁻⁴. TB pericarditis is less common but provides a prototypic example of the association
123 of EPTB with HIV co-infection^{17,18}. We therefore performed head-to-head comparison of the best performing
124 candidate RNA biomarkers from our previous studies^{11,16} among people being evaluated for TB lymphadenitis
125 or pericarditis at a referral centre in a hyper-endemic setting for TB and HIV infection. We benchmarked RNA
126 biomarker performance against CRP and the WHO target product profile (TPP) for a blood-based triage test
127 aiming to achieve sensitivity of $\geq 90\%$ and specificity of $\geq 70\%$ ¹⁰ and evaluated comparative clinical utility by
128 decision curve analysis.

129 **Methods**

130 ***Regulatory approvals and reporting standards***

131 The study was approved by the Stellenbosch University Faculty of Health Sciences Research Ethics
132 Committee (N16/04/050) and the Western Cape Department of Health, South Africa (WC_2016RP15_762).
133 The study is reported in line with standards for reporting diagnostic accuracy studies (STARD) guidance¹⁹.

134 ***Study cohort***

135 Consecutive adults referred for routine investigation by invasive sampling for TB lymphadenitis (January 2017
136 - March 2019) or TB pericarditis (November 2016 - January 2022) were recruited from a tertiary hospital in
137 Cape Town (South Africa). For the lymphadenitis cohort, patients who had received TB treatment within 2
138 months prior to presentation were excluded. For the pericarditis cohort, we included people up to 2 weeks after
139 TB treatment initiation. Subsets of the patients included in the present study contributed to a diagnostic
140 accuracy study of Xpert MTB/RIF Ultra (Ultra) in TB lymphadenitis²⁰, and evaluation of microbiota in TB
141 lymphadenitis²¹ or TB pericarditis²². Demographic characteristics, laboratory confirmed HIV status and self-
142 reported TB treatment (within 12 weeks of enrolment) were recorded for all participants. In each cohort,
143 diagnostic testing on samples from the site of disease included Xpert MTB/RIF (Xpert) or Ultra, with or without
144 liquid culture for *Mycobacterium tuberculosis* (Mtb), and cytology performed on lymph node aspirates
145 according to pre-defined algorithms (Supplementary Figure 1). For both cohorts, the results from sputum
146 smear microscopy, Mtb culture and molecular testing on other non-site of disease fluids conducted as part of
147 routine care were also recorded where available. Except for site-of-disease Ultra, all other investigations were
148 performed as part of routine care.

149 ***Measurement of blood RNA biomarkers and CRP***

150 Serum and blood RNA (collected in Tempus™ tubes; Ambion Life Technologies) samples were taken at
151 recruitment and stored at -80°C. Seven concise blood RNA signatures selected from the best performing
152 biomarkers of TB in our previous comparative studies^{11,16} were measured using the Nanostring™ platform as
153 described previously²³. Each signature was named using the first author's surname from the original publication
154 where it was derived followed by the number of component genes, except for BATF2 (a single transcript) and
155 RISK6 (named by the original investigators). These included the following signatures: BATF2²⁴, Gliddon³²⁵,
156 RISK6²⁶, Roe³²⁷, Suliman⁴²⁸, Sweeney³²⁹ and Darboe11 (derived from Zak16)³⁰. Blood RNA signature Z-
157 scores were calculated by subtracting the mean and dividing by the standard deviation of blood RNA samples
158 (N=48) from a multi-ethnic healthy control population of individuals with latent TB^{23,31}, measured using the
159 same Nanostring code-set batches. All samples were processed across two code-set batches. Distributions of
160 the processed gene level data across the two code-set batches suggested a small batch effect (Supplementary
161 Figure 2). We therefore performed batch correction with the ComBat function from the sva package in our
162 primary analyses, as previously²³ (Supplementary Figure 3-4). Serum CRP was measured on biobanked
163 serum using the Cobas high-sensitive immunoturbidimetric assay (Roche Diagnostics Limited, Burgess Hill,
164 UK).

165 ***Reference standards***

166 Our primary reference standard for TB in both cohorts was a positive Mtb culture or molecular test (Xpert or
167 Ultra, excluding 'trace' results) on samples from the site of disease or sputum. In sensitivity analyses, we
168 examined a range of alternative reference standards where we: (a) included Ultra 'trace' results as positive;
169 (b) included patients commenced on TB treatment within 12 weeks as TB; and (c) included cytology or
170 histology consistent with TB, as defined by evidence of necrotising granulomas.

171 ***Primary analysis***

172 All analyses were conducted using R (version 4.0.2). From the parent cohorts, we excluded participants without
173 RNA (n=58), CRP (n=6) or primary reference standard (n=2) data. In our primary analysis, we quantified area
174 under the receiver operating characteristic curve (AUROC) and 95% confidence intervals (CI)³² for each
175 biomarker, and CRP, to discriminate between patients with and without TB across both clinical syndromes,

176 since we observed similar performance in each cohort. We compared AUROCs for each RNA signature to
177 CRP using paired DeLong tests, with adjustment for multiple testing using a Benjamini-Hochberg correction.
178 Sensitivity, specificity and predictive values for each biomarker were calculated at different test thresholds: two
179 standard scores above the mean of the healthy control population (Z2) for the RNA signatures, 10 mg/L for
180 CRP, and at the Youden Index of each ROC curve. In order to benchmark test performance against the WHO
181 TPP¹⁰, we also calculated the specificity and predictive value of each biomarker at thresholds that achieved
182 90% sensitivity.

183 **Statistical power**

184 The sample size of each cohort was primarily determined by the number of participants in the parent studies
185 for which blood RNA, CRP and reference standard results were available. We calculated statistical precision
186 in PASS 2024 (Power Analysis and Sample Size Software, National Council for Social Studies), using
187 published models for estimates of sample size calculations in diagnostic tests^{33,34}. Our sample sizes provided
188 >80% power to test whether each biomarker could achieve the WHO TPP thresholds of 90% sensitivity with a
189 5% confidence interval and 70% specificity with 10% confidence interval (Supplementary Figure 5).

190 **Secondary analyses**

191 In secondary analyses, we evaluated biomarker performance stratified by disease site. We also performed
192 subgroup analyses by HIV status, and by HIV treatment status for HIV positive cases. The clinical utility of
193 candidate TB screening strategies was assessed by decision curve analysis using the 'rmda' package as
194 previously described^{12,23} to evaluate net benefit for the best performing blood RNA biomarker (at a threshold
195 of Z2) to guide confirmatory testing, in comparison to confirmatory testing for all, confirmatory testing for none,
196 and confirmatory testing guided by CRP (at thresholds of ≥ 5 mg/L and ≥ 10 mg/L). In addition to the alternative
197 reference standard definitions, we also performed a sensitivity analysis without batch correction.

198 **Role of the funding source**

199 The funder had no role in study design, data collection, data analysis, data interpretation, writing of the report,
200 or decision to submit for publication. The corresponding authors had full access to all the data in the study and
201 had final responsibility for the decision to submit for publication.

202 **Results**

203 **Characteristics of the study cohorts**

204 The pooled cohort comprised 440 individuals, of whom 66 people were excluded because they had any one
205 of missing microbiological, CRP or RNA results (Supplementary Table 1). The excluded participants were
206 generally comparable to those included in the analysis (Supplementary Table 1). Among the 374 participants
207 included in the analysis, 275 had lymphadenitis and 99 had pericarditis (Table 1, Figure 1). Median age was
208 38 years (interquartile range 31-48), 181/374 (48%) were female and 200 (54%) were PLWH, of whom 95/198
209 (48%) with known antiretroviral therapy status were receiving antiretroviral therapy at enrolment.

210 204/374 (55%) of included participants met the primary reference standard for TB of a positive culture or
211 molecular test for Mtb. Of these, 20/204 (10%) had positive Mtb sputum culture or sputum molecular tests.
212 The prevalence of microbiologically confirmed TB was 150/275 (55%) among people with lymphadenitis, and
213 54/99 (55%) among those with pericarditis. In the lymphadenitis cohort, the majority of people with known site
214 of disease (199/273; 73%) had cervical lymphadenitis, of whom 122/190 (61%) met the primary reference
215 standard.

216 **Diagnostic accuracy of blood RNA signatures and CRP for pooled analysis of Tb lymphadenitis and** 217 **pericarditis.**

218 In the primary analysis, all blood RNA biomarkers showed similar diagnostic accuracy to identify TB cases with
219 microbiologically confirmed TB, with AUROC point estimates ranging 0.77-0.82 (Figure 2, Table 2). All the
220 blood RNA biomarkers achieved statistically better AUROC than CRP with adjusted p-values of <0.05. The
221 Roe3 signature achieved the highest AUROC point estimate of 0.82 (95% CI 0.77-0.86). By comparison, CRP

222 achieved an AUROC of 0.61 (0.56-0.67). At pre-defined Z2 test thresholds for the blood RNA signatures, Roe3
223 achieved 78% (72-83) sensitivity and 69% (62-75) specificity. A pre-defined test threshold of 10 mg/L for CRP,
224 which we have assessed previously as a triage test for pulmonary TB¹², achieved a sensitivity of 88.3% (77-
225 87) and specificity of 35% (29-43). When fixing the sensitivity of each test to 90% (in line with the WHO TPP),
226 Roe3 achieved 52% (45-60) specificity and CRP achieved 27% (21-34) specificity, both below the WHO
227 specificity target of 70% (Supplementary Table 2).

228 **Secondary analyses**

229 In secondary analyses, we evaluated the performance of the biomarkers stratified by disease cohort. We found
230 their performance to be comparable in lymphadenitis and pericarditis (Supplementary Figure 6-7,
231 Supplementary Table 3-4). Of note, among TB cases, the CRP levels in the pericarditis cohort were
232 significantly higher than that of lymphadenitis cases. This difference was less evident among the blood RNA
233 signatures (Figure 3). Biomarker diagnostic accuracy using alternate reference standards was similar to that
234 of the primary analysis. The point estimates for biomarker diagnostic accuracy among PLWH were lower than
235 those without HIV infection but did not reach statistically significant differences (Supplementary Table 5).

236 In addition, we used the pooled dataset to evaluate clinical utility of Roe3 and that of CRP, using decision
237 curve analysis, benchmarked against the alternative approaches of undertaking confirmatory diagnostic
238 investigations in all or none³⁵. This analysis quantifies the net benefit of a given approach, representing the
239 trade-off between the true positive rate and a weighted false positive rate across a range of test threshold
240 probabilities that trigger an intervention. The test threshold probabilities (reflecting the perceived cost:benefit
241 ratio that triggers an intervention) are used for weighting the false positive rate. The intervention triggered by
242 a triage test would be to proceed to confirmatory diagnostic investigations. Therefore, the triage test threshold
243 probability can be considered as the number willing to investigate to identify each TB case. The Roe3 blood
244 RNA biomarker (>Z2) achieved greater net benefit than confirmatory testing for all at a test threshold probability
245 >0.28. By comparison CRP (>10 mg/L) provided greater net benefit than confirmatory testing for all at a test
246 threshold probability >0.37 (Figure 4). These data suggest that using blood RNA biomarkers to direct use of
247 confirmatory testing provides the best approach for comparable services in HIV/TB hyperendemic settings
248 where the number willing to test by confirmatory diagnostics is fewer than 4 for each case of EPTB. In settings
249 willing to test more than 4 people with a confirmatory test for each true case of EPTB, a test all approach
250 achieves greater net benefit than a triage approach using any of the biomarkers tested in the present study.

251 **Discussion**

252 To the best of our knowledge, our findings provide the first diagnostic accuracy study of blood RNA biomarkers
253 focusing on extrapulmonary TB. We undertook our study in a hyperendemic setting for both TB and HIV. In a
254 pooled data set of people under investigation for TB lymphadenitis or pericarditis, all the blood RNA biomarkers
255 tested had comparable performance with similar AUROCs as previously reported for pulmonary TB^{11,36}. For
256 most biomarkers, blood RNA signatures showed higher point estimates for accuracy in people without HIV
257 compared to in PLWH, but with overlapping confidence intervals. In addition, we undertook head-to-head
258 comparison of blood RNA biomarkers to serum CRP concentrations. In contrast to previous reports, where
259 CRP measurements achieve similar diagnostic accuracy to blood RNA biomarkers in pulmonary TB^{12,23}, we
260 found CRP was significantly inferior to blood RNA biomarkers for the EPTB syndromes tested here, both
261 among PLWH and people without HIV.

262 Importantly sputum tests identified less than 10% of the TB cases in our pooled analysis of TB lymphadenitis
263 and pericarditis, often because sputum acquisition was not attempted. Given that people with extrapulmonary
264 TB may have concomitant pulmonary TB, this highlights both the importance of strengthening sputum
265 collection in addition to sampling from the site of disease in EPTB. Therefore, we envisioned the primary
266 application of biomarkers of EPTB as triage tests to prioritise use of invasive sampling for confirmatory testing.
267 The application of such tests in a primary care setting may prioritise patients for referral to secondary care
268 reducing costs and attrition across the cascade of care. In this context, none of the biomarkers tested met the
269 combined sensitivity of >90% and specificity >70% recommended by WHO¹⁰. Nonetheless, we assessed their
270 potential clinical utility by decision curve analysis. The best performing blood RNA biomarker showed greater

271 net benefit than either CRP or unrestricted approaches to trigger invasive confirmatory testing for services
272 aiming to reduce the number needed to investigate to less than 4 to identify each case of TB. In settings with
273 such high TB prevalence and therefore high prior probability of TB, unrestricted approaches to confirmatory
274 testing may be preferable. Settings with lower prior probability of TB may be expected to derive greater benefit
275 from triage tests.

276 In our secondary analyses, we showed that the performance of the biomarkers was equivalent in TB
277 lymphadenitis and pericarditis. In addition, the use of alternative reference standards did not significantly alter
278 our results. We focused on selected blood RNA biomarkers, previously identified by systematic review, which
279 showed the best performance for diagnosis of pre-clinical/incipient as well as symptomatic TB and were
280 sufficiently concise to undertake multiplex measurements using a validated Nanostring platform^{16,23,36}. We
281 have previously shown in a diagnostic accuracy study for pulmonary TB among PLWH that these RNA
282 biomarkers show greater correlation to each other than to CRP²³, suggesting that TB associated blood
283 transcriptional changes are regulated differently to that of CRP levels. This interpretation is consistent with the
284 findings in the present study showing that CRP does not identify TB cases in EPTB as well as blood RNA
285 biomarkers. It is interesting that CRP levels were substantially higher in TB pericarditis than TB lymphadenitis
286 cases. This difference was absent or less significant among the blood RNA signatures, suggesting a hierarchy
287 for recruitment of immunological pathways with increasing inflammatory manifestations of disease. We
288 propose that TNF and IFN signalling, which we previously identified as drivers of the blood RNA biomarkers
289 of TB¹⁶ are more conserved across the spectrum of TB disease-sites, than the immunological pathways that
290 regulate CRP, more strongly linked to IL-6 signalling³⁷. If so, then despite recent interest in adopting point-of-
291 care CRP as a triage test for TB^{12,15,38} we may expect that blood RNA biomarkers provide a more consistent
292 performance for the range of disease manifestations beyond pulmonary TB. Interestingly, IL-6 signalling has
293 also been associated with risk of TB³⁹ and its immunopathogenesis³¹ consistent with the finding that CRP
294 levels are higher in TB pericarditis that reflects a more severe variant of disease than TB lymphadenitis.

295 The strengths of our study include robust classification of TB based on highly specific microbiological tests in
296 the primary analysis, complemented by sensitivity analyses using alternative reference standards; head-to-
297 head comparison of multiple blood RNA signatures with CRP; inclusion of two distinct EPTB syndromes; and
298 adequate sample sizes to evaluate the performance of biomarkers with a good level of precision. Our study
299 also has important limitations. The single site design may limit the generalisability of our findings, particularly
300 for settings with lower prevalence of TB and HIV. Future studies of EPTB in different settings will be required
301 to address this limitation. Settings with lower prior probability of TB, for example earlier in the cascade of care
302 or lower prevalence settings may reveal much greater differential clinical utility between biomarker triage and
303 unrestricted approaches to confirmatory testing for EPTB. In addition, we cannot confidently generalise our
304 findings across the full spectrum of EPTB diseases. The similarities in RNA biomarker performance between
305 TB lymphadenitis and TB pericarditis is a valuable starting point, but future studies will require to test a wider
306 range of EPTB syndromes.

307 Notwithstanding these limitations, our study substantially extends our insights into the real-world evaluation of
308 the leading candidates for TB diagnostic triage tests by providing the largest available data for EPTB. Next
309 generation blood RNA biomarkers show some clinical utility, but fall short of the desired accuracy targets.
310 Importantly, blood CRP measurements show significantly inferior accuracy to blood RNA biomarkers in EPTB,
311 and to that previously reported accuracy in pulmonary TB. We conclude that CRP based triage is unlikely to
312 be useful in this context. Multivariable models incorporating clinical, epidemiological and laboratory
313 measurements are urgently needed to overcome the limitations of individual biomarker approaches, alongside
314 further innovation in discovery of novel diagnostic biomarkers.

315 **Footnotes**

316 ***Author contributions***

317 Conceived and designed the study: GT, MN

318 Sample and clinical data collection: SM, BR, GN, HM, BD, HT, ZP, SN, DM

319 Laboratory analysis: TM, SM, AC, PK
320 Data analysis: TM, SM, BR, RKG, CJC, AC, PK, GT, MN
321 Manuscript preparation: TM, SM, RKG, BR, GT, MN with input from all authors

322 **Funding**

323 This study was supported by funding from South Africa Medical Research Council (MRC-RFA-IFSP-01-2013),
324 European and Developing Countries Clinical Trials Partnership (EDCTP)2 (SF1401, OPTIMAL DIAGNOSIS)
325 and NIH/NIAD (U01AI152087). In addition, MN acknowledges support from the Wellcome Trust
326 (207511/Z/17/Z) and NIHR Biomedical Research Funding to UCL and UCLH; RKG acknowledges support
327 from National Institute for Health Research (NIHR302829) and the Royal College of Physicians; CJC
328 acknowledges support from the Wellcome Trust (C). GT reports funding from the EDCTP2 programme
329 supported by the EU (RIA2018D-2509, PreFIT; RIA2018D-2493, SeroSelectTB; RIA2020I-3305, CAGE-TB)
330 and the National Institutes of Health (D43TW010350; U01AI152087; U54EB027049; R01AI136894).

331 **Declaration of interests**

332 MN has a patent granted in relation to blood transcriptomic biomarkers of tuberculosis. All other authors declare
333 no competing interests.

334 **Data availability statement**

335 Processed Nanostring and CRP data with accompanying metadata will be provided as supplementary data at
336 the time of peer-reviewed publication.


337 **References**

- 338 1 World Health Organization. Global Tuberculosis Report 2022. [https://www.who.int/teams/global-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)
339 [tuberculosis-programme/tb-reports/global-tuberculosis-report-2022](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022).
- 340 2 Pang Y, An J, Shu W, *et al*. Epidemiology of Extrapulmonary Tuberculosis among Inpatients, China, 2008–
341 2017 - Volume 25, Number 3—March 2019 - Emerging Infectious Diseases journal - CDC.
342 DOI:10.3201/eid2503.180572.
- 343 3 Sandgren A, Hollo V, van der Werf MJ. Extrapulmonary tuberculosis in the European Union and European
344 Economic Area, 2002 to 2011. *Euro Surveill* 2013; **18**: 20431.
- 345 4 Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis
346 in the United States, 1993-2006. *Clin Infect Dis* 2009; **49**: 1350–7.
- 347 5 Adada H, Valley MA, Nour SA, *et al*. Epidemiology of extra-pulmonary tuberculosis in the United States:
348 high rates persist in the post-HIV era. *Int J Tuberc Lung Dis* 2014; **18**: 1516–21.
- 349 6 Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for
350 the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2014;
351 **44**: 435–46.
- 352 7 Kohli M, Schiller I, Dendukuri N, *et al*. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin
353 resistance. *Cochrane Database of Systematic Reviews* 2018. DOI:10.1002/14651858.CD012768.pub2.
- 354 8 Naing C, Mak JW, Maung M, Wong SF, Kassim AIBM. Meta-analysis: the association between HIV infection
355 and extrapulmonary tuberculosis. *Lung* 2013; **191**: 27–34.
- 356 9 Shivakoti R, Sharma D, Mamoon G, Pham K. Association of HIV infection with extrapulmonary tuberculosis:
357 a systematic review. *Infection* 2017; **45**: 11–21.
- 358 10 WHO | High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting.
359 World Health Organisation, 2014 http://www.who.int/tb/publications/tpp_report/en/.

- 360 11 Turner CT, Gupta RK, Tsaliki E, *et al.* Blood transcriptional biomarkers for active pulmonary tuberculosis in
361 a high-burden setting: a prospective, observational, diagnostic accuracy study. *The Lancet Respiratory*
362 *Medicine* 2020; **8**: 407–19.
- 363 12 Calderwood CJ, Reeve BW, Mann T, *et al.* Clinical utility of C-reactive protein-based triage for presumptive
364 pulmonary tuberculosis in South African adults. *J Infect* 2022; : S0163-4453(22)00639-9.
- 365 13 Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest* 2003; **111**: 1805–12.
- 366 14 Dhana A, Hamada Y, Kengne AP, *et al.* Tuberculosis screening among ambulatory people living with HIV:
367 a systematic review and individual participant data meta-analysis. *The Lancet Infectious Diseases* 2022;
368 **22**: 507–18.
- 369 15 Byron WP Reeve, Gcobisa Ndlangalavu, Hridesh Mishra, *et al.* Point-of-care C-reactive protein and Xpert
370 MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a
371 prospective diagnostic accuracy study. *medRxiv* 2023; : 2023.05.30.23290716.
- 372 16 Gupta RK, Turner CT, Venturini C, *et al.* Concise whole blood transcriptional signatures for incipient
373 tuberculosis: a systematic review and patient-level pooled meta-analysis. *Lancet Respir Med* 2020;
374 published online Jan 17. DOI:10.1016/S2213-2600(19)30282-6.
- 375 17 Ntsekhe M, Hakim J. Impact of Human Immunodeficiency Virus Infection on Cardiovascular Disease in
376 Africa. *Circulation* 2005; **112**: 3602–7.
- 377 18 Cegielski JP, Lwakatare J, Dukes CS, *et al.* Tuberculous pericarditis in Tanzanian patients with and without
378 HIV infection. *Tuber Lung Dis* 1994; **75**: 429–34.
- 379 19 Cohen JF, Korevaar DA, Altman DG, *et al.* STARD 2015 guidelines for reporting diagnostic accuracy
380 studies: explanation and elaboration. *BMJ Open* 2016; **6**: e012799.
- 381 20 Minnies S, Reeve BWP, Rockman L, *et al.* Xpert MTB/RIF Ultra Is Highly Sensitive for the Diagnosis of
382 Tuberculosis Lymphadenitis in a High-HIV Setting. *J Clin Microbiol* 2021; **59**: e0131621.
- 383 21 Nyawo GR, Naidoo CC, Wu B, *et al.* More than Mycobacterium tuberculosis: site-of-disease microbial
384 communities, and their functional and clinical profiles in tuberculous lymphadenitis. *Thorax* 2023; **78**: 297–
385 308.
- 386 22 Nyawo G, Naidoo C, Wu BG, *et al.* Bad company? The pericardium microbiome in people investigated for
387 tuberculosis pericarditis in an HIV-prevalent setting. *medRxiv* 2024; : 2024.04.26.24306431.
- 388 23 Mann T, Gupta RK, Reeve BWP, *et al.* Blood RNA biomarkers for tuberculosis screening in people living
389 with HIV before antiretroviral therapy initiation: a diagnostic accuracy study. *The Lancet Global Health* 2024;
390 published online April 4. DOI:10.1016/S2214-109X(24)00029-9.
- 391 24 Roe JK, Thomas N, Gil E, *et al.* Blood transcriptomic diagnosis of pulmonary and extrapulmonary
392 tuberculosis. *JCI Insight* 2016; **1**: e87238.
- 393 25 Gliddon HD, Kaforou M, Alikian M, *et al.* Identification of Reduced Host Transcriptomic Signatures for
394 Tuberculosis Disease and Digital PCR-Based Validation and Quantification. *Front Immunol* 2021; **12**:
395 637164.
- 396 26 Penn-Nicholson A, Mbandi SK, Thompson E, *et al.* RISK6, a 6-gene transcriptomic signature of TB disease
397 risk, diagnosis and treatment response. *Sci Rep* 2020; **10**: 8629.
- 398 27 Roe J, Venturini C, Gupta RK, *et al.* Blood Transcriptomic Stratification of Short-term Risk in Contacts of
399 Tuberculosis. *Clin Infect Dis* 2020; **70**: 731–7.
- 400 28 Suliman S, Thompson EG, Sutherland J, *et al.* Four-Gene Pan-African Blood Signature Predicts
401 Progression to Tuberculosis. *Am J Respir Crit Care Med* 2018; **197**: 1198–208.

- 402 29 Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary
403 tuberculosis: a multicohort analysis. *Lancet Respir Med* 2016; published online Feb 19.
404 DOI:10.1016/S2213-2600(16)00048-5.
- 405 30 Darboe F, Mbandi SK, Thompson EG, *et al.* Diagnostic performance of an optimized transcriptomic
406 signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells. *Tuberculosis* 2018;
407 **108**: 124–6.
- 408 31 Pollara G, Turner CT, Rosenheim J, *et al.* Exaggerated IL-17A activity in human in vivo recall responses
409 discriminates active tuberculosis from latent infection and cured disease. *Sci Transl Med* 2021; **13**:
410 eabg7673.
- 411 32 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver
412 operating characteristic curves: a nonparametric approach. *Biometrics* 1988; **44**: 837–45.
- 413 33 Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. *J Biomed Inform*
414 2014; **48**: 193–204.
- 415 34 Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods.
416 *Stat Med* 1998; **17**: 857–72.
- 417 35 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis*
418 *Making* 2006; **26**: 565–74.
- 419 36 Mendelsohn SC, Mbandi SK, Fiore-Gartland A, *et al.* Prospective multicentre head-to-head validation of
420 host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. *Commun Med (London)*
421 2022; **2**: 26.
- 422 37 Said S, Pazoki R, Karhunen V, *et al.* Genetic analysis of over half a million people characterises C-reactive
423 protein loci. *Nat Commun* 2022; **13**: 2198.
- 424 38 Ruperez M, Shanaube K, Mureithi L, *et al.* Use of point-of-care C-reactive protein testing for screening of
425 tuberculosis in the community in high-burden settings: a prospective, cross-sectional study in Zambia and
426 South Africa. *The Lancet Global Health* 2023; **11**: e704–14.
- 427 39 Hamilton F, Schurz H, Yates TA, *et al.* Altered IL-6 signalling and risk of tuberculosis disease: a meta-
428 analysis and Mendelian randomisation study. *medRxiv* 2023; : 2023.02.07.23285472.
- 429

430 **Figure 1**



431 **Study cohort consort diagrams**

432 Consort diagrams for recruitment and analysis of study participants under investigation for lymphadenitis or
433 pericarditis.

434 **Table 1**

435 **Summary characteristics of lymphadenitis and pericarditis cohorts**

Characteristic		Overall N = 374	Lymph node N = 275	Pericardial N = 99
Age (years)		38 (31, 48)	38 (31, 46)	37 (30, 49)
Gender	Female	181 (48%)	138 (50%)	43 (43%)
	Male	193 (52%)	137 (50%)	56 (57%)
Previous TB	Yes	91 (24%)	70 (26%)	21 (21%)
	Missing	2	2	0
HIV status	Negative	172 (46%)	131 (48%)	41 (41%)
	Positive	200 (54%)	142 (52%)	58 (59%)
	Missing	2	2	0
On antiretroviral therapy*	Yes	95 (48%)	75 (54%)	20 (34%)
	Missing	2	2	0
CD4 (cells/mm ³)	Yes	158 (49, 288)	158 (46, 272)	176 (52, 332)
	Missing	175	133	42
CD4 <200 (cells/mm ³)	Yes	118 (59%)	84 (59%)	34 (60%)
	Missing	175	133	42
Site of disease molecular tests (N)	0	2 (0.5%)	2 (0.7%)	0 (0%)
	1	156 (42%)	156 (57%)	0 (0%)
	2	124 (33%)	117 (43%)	7 (7.1%)
	3	64 (17%)	0 (0%)	64 (65%)
	4	28 (7.5%)	0 (0%)	28 (28%)
Fluid Xpert or Ultra	Negative	154 (41%)	117 (43%)	37 (37%)
	Positive	218 (59%)	156 (57%)	62 (63%)
	Not done	2	2	0
Fluid culture	Negative	174 (67%)	121 (74%)	53 (56%)
	Positive	84 (33%)	42 (26%)	42 (44%)
	Not done	116	112	4
Biopsy culture	Negative	8 (38%)	0 (NA%)	8 (38%)
	Positive	13 (62%)	0 (NA%)	13 (62%)
	Not done	353	275	78
Cytology consistent with TB	Yes	126 (36%)	126 (49%)	0 (0%)
	Not done	28	16	12
Histology consistent with TB	Yes	9 (39%)	0 (NA%)	9 (39%)
	Not done	351	275	76
Sputum culture or molecular	Negative	39 (66%)	22 (63%)	17 (71%)
	Positive	20 (34%)	13 (37%)	7 (29%)
	Not done	315	240	75
Culture or molecular test positive (site or sputum)		204 (55%)	150 (55%)	54 (55%)
Started TB treatment	Yes	221 (61%)	143 (54%)	78 (79%)
	Missing	9	9	0

436 Data represent median (interquartile range) or number (%). *Limited to HIV positive participants.


437 **Table 2**

438 ***Diagnostic accuracy of blood RNA biomarkers and CRP for TB lymphadenitis and pericarditis.***

Signature	AUROC	Sensitivity	Specificity	PPV	NPV	Triage positive	NNT(+)	NNT(-)
Roe3	0.82 (0.77-0.86)	0.78 (0.72-0.83)	0.69 (0.62-0.75)	0.75 (0.69-0.8)	0.72 (0.65-0.79)	0.57 (0.52-0.62)	1.3 (1.2-1.5)	3.6 (2.8-4.7)
Darboe11	0.81 (0.76-0.85)	0.77 (0.71-0.83)	0.66 (0.59-0.73)	0.73 (0.67-0.79)	0.71 (0.64-0.78)	0.57 (0.52-0.62)	1.4 (1.3-1.5)	3.5 (2.7-4.5)
BATF2	0.8 (0.76-0.85)	0.83 (0.77-0.87)	0.59 (0.51-0.66)	0.71 (0.65-0.76)	0.74 (0.66-0.81)	0.64 (0.59-0.69)	1.4 (1.3-1.5)	3.9 (2.9-5.2)
Sweeney3	0.78 (0.74-0.83)	0.76 (0.7-0.82)	0.65 (0.57-0.71)	0.72 (0.66-0.78)	0.7 (0.62-0.76)	0.58 (0.53-0.63)	1.4 (1.3-1.5)	3.3 (2.6-4.2)
Gliddon3	0.78 (0.73-0.82)	0.92 (0.87-0.95)	0.37 (0.3-0.45)	0.64 (0.58-0.69)	0.79 (0.69-0.86)	0.79 (0.74-0.82)	1.6 (1.5-1.7)	4.7 (3.2-7.3)
Risk6	0.77 (0.72-0.82)	0.86 (0.81-0.9)	0.45 (0.38-0.53)	0.65 (0.6-0.71)	0.73 (0.64-0.81)	0.72 (0.67-0.76)	1.5 (1.4-1.7)	3.7 (2.8-5.2)
Suliman4	0.73 (0.68-0.78)	0.78 (0.72-0.83)	0.54 (0.47-0.61)	0.67 (0.61-0.73)	0.67 (0.59-0.74)	0.63 (0.58-0.68)	1.5 (1.4-1.6)	3 (2.4-3.9)
CRP	0.61 (0.56-0.67)	0.83 (0.77-0.87)	0.35 (0.29-0.43)	0.61 (0.55-0.66)	0.63 (0.53-0.72)	0.75 (0.7-0.79)	1.7 (1.5-1.8)	2.7 (2.1-3.6)


439 Performance indexed against the reference standard of positive culture or molecular test (Xpert MTB/RIF or Xpert Ultra, excluding 'trace' results) on samples from the
 440 site of disease or sputum. Data shown as proportions \pm 95% confidence intervals. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value
 441 (NPV), the triage positive rate and number needed to test for each positive (NNT+) or negative (NNT-) cased were calculated at Z2 threshold for the blood RNA
 442 biomarkers and 10 mg/L threshold for CRP.

443 **Figure 2**



444 **Blood RNA biomarker discrimination of primary reference standard for lymph node and pericardial TB.**
445 Scores shown as Z-scores for RNA signatures, and log-2 transformed CRP (mg/L), stratified by disease cohort
446 (green = presumptive lymphadenitis and yellow = presumptive pericarditis). Discrimination of the pooled data
447 set presented as area under the receiver operating characteristic curve (AUC), with 95% confidence intervals.


448 **Figure 3**



449 **Biomarker scores for TB lymphadenitis and pericarditis**

450 Z-scores for RNA signatures, and log-2 transformed CRP (mg/L) are shown for microbiologically confirmed TB
451 stratified by disease site and compared by Wilcoxon Rank Test.

452 **Figure 4**



453 **Decision curve analysis for alternative triage strategies to trigger confirmatory investigations for TB**
454 Net benefit (true positive rate - false positive rate weighted by cost:benefit ratio) for investigate all and
455 investigate none approaches across the range of threshold probabilities that a service may use to trigger
456 confirmatory investigations for TB is compared to that of decisions to investigate triggered by each of triage
457 strategies indicated: CRP (≥ 5 and ≥ 10 mg/L), and Roe (Z2).